Trinity Biotech plc (TRIB) ADR Each Representing 20 Ord Shares SPON

Sell:$1.06Buy:$1.09$0.01 (0.93%)

NASDAQ:0.76%
Market closed |
Prices delayed by at least 15 minutes
Sell:$1.06
Buy:$1.09
Change:$0.01 (0.93%)
Market closed |
Prices delayed by at least 15 minutes
Sell:$1.06
Buy:$1.09
Change:$0.01 (0.93%)
Market closed |
Prices delayed by at least 15 minutes

Company Information

About this company

Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.

Key people

John Gillard
President, Chief Executive Officer, Executive Director
Ronan O'caoimh
Founder, Executive Director
Susan O'Connor
Interim Chief Financial Officer
Gary Keating
Chief Technology Officer
Eibhlin Kelly
Chief Information Officer
Matthew Wictome
Vice President - Quality and Regulatory Affairs
James Walsh
Executive Director - Business Development
Colm Molloy
Group Director of Human Resources and Culture
Tom Lindsay
Non-Executive Independent Director
Andrew Omidvar
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    TRIB
  • Location
    Ireland
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US8964385046
  • Market cap
    $19.56m
  • Employees
    401
  • Shares in issue
    33.08m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.